Tau protein Inhibitors
1 drugsAbout Tau protein
Tau protein, a microtubule-associated protein primarily in neurons, stabilizes microtubules essential for cellular structure and transport. In neurodegenerative diseases, Tau becomes hyperphosphorylated and misfolded, forming neurofibrillary tangles. These tangles are a hallmark of diseases affecting the central nervous system (CNS).
Tau's role in neurodegenerative disease pathology makes it a therapeutic target for CNS disorders. However, there is currently no genetic evidence directly linking Tau to specific diseases in this dataset. Targeting Tau aggregation or phosphorylation could potentially slow or reverse disease progression.
Currently, one FDA-approved drug, TAUVID, targets Tau protein for CNS indications. TAUVID, a small molecule, was first approved in 2020 by AVID Radiopharmaceuticals Inc.
Top Tau protein Drugs
AVID Radiopharmaceuticals Inc. is the only company with an approved drug targeting Tau.
Low competition presents an opportunity for new entrants, but also indicates potential challenges in the target's tractability.
Tau protein Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Tau protein, using small molecule modality.
Explore alternative modalities like antibodies or gene therapies to differentiate from existing treatments.
Tau protein Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Tau protein. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Tau protein Drug Approval Timeline (2020 - 2020)
TAUVID was the first and most recent drug approved in 2020, creating a short approval span of 1 year.
The recent approval suggests renewed interest in Tau as a target, but the lack of subsequent approvals indicates potential hurdles.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Tau protein. A trial counts if an approved drug acting on Tau protein is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.